Arctic Bioscience AS ABS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- NOK 10.40
- Day Range
- NOK 9.85–10.00
- 52-Week Range
- NOK 7.54–12.00
- Bid/Ask
- NOK 9.90 / NOK 10.20
- Market Cap
- NOK 249.89 Mil
- Volume/Avg
- 900 / 7,321
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.45
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Arctic Bioscience AS is a Norwegian biotechnology company. The company is focused on developing products and solutions based on bioactive marine compounds. The product portfolio includes nutraceuticals and pharmaceuticals. It is currently developing a novel, cost-efficient oral treatment (HRO350) for mild-to-moderate psoriasis. Its nutraceutical products are sold globally to both B2C and B2B under the Romega brand.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 20
Valuation
|
Metric
|
ABS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.97 |
Price/Sales | 7.45 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ABS
|
|---|---|
Quick Ratio | 4.00 |
Current Ratio | 5.05 |
Interest Coverage | −317.55 |
Quick Ratio
ABS
Profitability
|
Metric
|
ABS
|
|---|---|
Return on Assets (Normalized) | −14.38% |
Return on Equity (Normalized) | −16.47% |
Return on Invested Capital (Normalized) | −17.23% |
Return on Assets
ABS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Kmgypfylmy | Pln | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vsjfdkjw | Kdywm | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gkbmccspy | Mhygdg | $97.8 Bil | |
MRNA
| Moderna Inc | Yvxkzgl | Jnsv | $38.8 Bil | |
ARGX
| argenx SE ADR | Kqvgzrcs | Tzsn | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Rpvczgkrn | Gdsmr | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rfmwsjlfb | Ntlnpx | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xrvjjhm | Mtrkdm | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Splfytqdz | Pvrpjzk | $12.5 Bil | |
INCY
| Incyte Corp | Yvmpkqg | Dvykrl | $11.5 Bil |